Clinical Trial Update: A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating CRS profile optimization for glofitamab combined with gemcitabine and oxaliplatin in relapsed/refractory aggressive B-c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Glofitamab (glofitamab)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: B-Cell Non-Hodgkins Lymphoma | Phase 2 | Status: RECRUITING